# SBIR Phase II: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia by Leveraging Both Innate and Adaptive Immune Mechanisms

**Budget Signal Score:** 70/100

| Field | Value |
|---|---|
| Institution | ENABLE LIFE SCIENCES LLC |
| Location | FARMINGTON, CT |
| Project | SBIR Phase II: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia by Leveraging Both Innate and Adaptive Immune Mechanisms |
| Award amount | $1,244,469 |
| Obligated so far | $312,500 |
| Awarded | 2026-09-14 |
| Period | 2026-10-01 to 2028-09-30 |
| Program | SBIR Phase II |
| Directorate / division | TIP / SSB |
| Award ID | 2550729 |

## Why this score
- Award of $1M or more.
- Equipment- and compute-heavy field.

Source: U.S. National Science Foundation Awards API (https://www.nsf.gov/awardsearch/showAward?AWD_ID=2550729). Last refreshed: 2026-11-03T18:10:42.804Z.
Award data comes from the NSF Awards API and may be amended by NSF. Institution-level only; investigator contact details are not included. Informational only.